Diamond Biofund Inc is a Taiwan-based company primarily engaged in the venture capital and general investment industries. The Company focuses on investments in the biotechnology and medical fields. Main investment areas include new drug research and development, high-end medical devices, innovative medical service technologies or models, medical access, and agricultural biotechnology. The Company's investments are primarily in the domestic sector.

Employees

Sector

Investment Management & Fund Operators

More about the company

Quotes

Date	Price	Change	Volume
20/08/26	NT$16.80	+3.70%	2,046,720
19/08/26	NT$16.20	-2.11%	965,144
18/08/26	NT$16.55	-2.65%	1,276,460
17/08/26	NT$17.00	+3.03%	1,493,658
14/08/26	NT$16.50	-4.90%	2,728,261

End-of-day quote Taiwan S.E.

More quotes

End-of-day quote Taiwan S.E. 20/08/2026			5-day change	1st Jan Change
16.80 ^TWD	+3.70%		-3.17%	+1.82%

08-11	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-06	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	14.34B 449M 384M 359M 329M 618M 42.95B 630M 4.25B 1.66B 21.52B 1.69B 1.65B 71.26B	P/E 2024	-11x	P/E 2025	-12x
Enterprise Value	10.54B 330M 283M 264M 242M 454M 31.57B 463M 3.13B 1.22B 15.82B 1.24B 1.21B 52.38B	EV / Sales 2024	-10.2x	EV / Sales 2025	-9.56x
Free-Float	16.24%	Yield 2024 *	-	Yield 2025	-

08-11	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-06	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-12	Diamond Biofund Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	Diamond Biofund Inc. Announces Financial Officer Changes, Effective December 22, 2025	CI
11-11	Diamond Biofund Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/08/25	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
09/05/25	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
26/02/25	Diamond Biofund Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/12/24	Diamond Biofund Logs Negative Revenue for Three Straight Months	MT
11/11/24	Diamond Biofund Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
09/08/24	Diamond Biofund Incurs Over NT$941 Million Loss in H1	MT
09/08/24	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
09/08/24	Stemcyte International, Inc. announced that it expects to receive $19.05 million in funding from Diamond Biofund Inc.	CI

1 day	+3.70%
1 week	-3.17%
Current month	+3.07%
1 month	-5.08%
3 months	+24.91%
6 months	+4.67%
Current year	+1.82%

Diamond Biofund Inc. Stock

Stocks

6901

TW0006901002

Investment Management & Fund Operators

Valuation: Diamond Biofund Inc.

Chart: Diamond Biofund Inc.

Latest news : Diamond Biofund Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Diamond Biofund Inc.

Other Investment Management & Fund Operators

Financials

Company Profile

Quotes

1 week	16.1	17
1 month	15.75	18.7
Current year	12.05	22.4
1 year	12.05	22.4
3 years	12.05	71.8
5 years	12.05	200.19
10 years	12.05	200.19

Manager	Title	Age	Since
Shu Ling Cheng CEO	Chief Executive Officer	-	-
Yuan Ting Wu DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Kung Ming Lu CHM	Chairman	-	-
Tsu Te Li BRD	Director/Board Member	-	-
Wan Chun Chen BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIAMOND BIOFUND INC.	+3.70%	-3.17%	-17.04%	-76.24%	449M
BLACKROCK, INC.	-1.65%	-3.64%	+1.01%	+70.06%	177B
UBS GROUP AG	-1.23%	-2.99%	+32.53%	+105.10%	164B
BANK OF NEW YORK MELLON CORPORATION (THE)	-1.58%	-3.09%	+55.30%	+257.20%	107B
BROOKFIELD CORPORATION	-2.04%	-9.14%	-3.68%	+90.99%	92.51B
BROOKFIELD ASSET MANAGEMENT LTD.	-2.21%	-8.59%	-13.66%	+56.26%	82.45B
STATE STREET CORPORATION	-1.47%	-3.57%	+63.62%	+169.42%	50.29B
AMERIPRISE FINANCIAL, INC.	-2.27%	-4.13%	+8.25%	+64.60%	48.33B
3I GROUP PLC	+2.02%	+2.33%	-30.06%	+51.23%	38.18B
NORTHERN TRUST CORPORATION	-1.56%	-4.18%	+42.72%	+137.83%	33.39B
Average	-0.66%	-3.47%	+13.90%	+92.65%	79.25B
Weighted average by Cap.	-1.12%	-4.14%	+17.42%	+111.34%

	2024	2025
Net sales	-2.23B -69.78M -59.74M -55.74M -51.15M -96.11M -6.68B -98M -661M -258M -3.35B -262M -256M -11.08B	-1.07B -33.6M -28.77M -26.84M -24.63M -46.28M -3.22B -47.19M -318M -124M -1.61B -126M -123M -5.33B
Net income	-2.52B -78.83M -67.5M -62.98M -57.79M -109M -7.54B -111M -747M -291M -3.78B -296M -290M -12.52B	-1.17B -36.78M -31.49M -29.38M -26.96M -50.66M -3.52B -51.65M -349M -136M -1.76B -138M -135M -5.84B
Net Debt	-5.01B -157M -134M -125M -115M -216M -15.02B -220M -1.49B -580M -7.52B -589M -576M -24.91B	-3.8B -119M -102M -94.97M -87.14M -164M -11.38B -167M -1.13B -439M -5.7B -446M -437M -18.87B